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Meningococcal disease occurs worldwide with incidence rates varying from 1 to 1000 cases per 100,000.
The causative organism, Neisseria meningitidis, is an obligate commensal of humans, which normally
colonizes the mucosa of the upper respiratory tract without causing invasive disease, a phenomenon
known as carriage. Studies using molecular methods have demonstrated the extensive genetic diversity
of meningocococci isolated from carriers, in contrast to a limited number of genetic types, known as theopulation structure
hyperinvasive lineages, associatedwith invasive disease. Population and evolutionarymodels that invoke
positive selection can be used to resolve the apparent paradox of virulent lineages persisting during the
global spread of a non-clonal andnormally commensal bacterium. The application of insights gained from
studies of meningococcal population biology and evolution is important in understanding the spread of
disease, as well as in vaccine development and implementation, especially with regard to the challenge
of producing comprehensive vaccines based on sub-capsular antigens and measuring their effectiveness.. Introduction
The sole ecological niche of Neisseria meningitidis is the mucosa
f the oropharynx of humans. Meningococcal colonization of the
espiratory tract, a phenomenon commonly referred to as car-
iage, represents a successful commensal relationship between the
ost and the bacterium, with the host experiencing no detectable
athology. On the other handdisease represents a failed or dysfunc-
ional relationship with the host [1]. Acquisition of N. meningitidis
emands person-to-person transmission via direct contact or
hrough dispersion of respiratory droplets from an infected to a
usceptible individual. Although often protected by a polysaccha-
ide capsule,meningococci are particularly sensitive to desiccation;
hus, spread from one individual to another requires close contact
2]. In closed or semi-closed settings, such as residential schools
ndmilitary recruit camps, transmission increasesdramatically and
arriage prevalence may approach 100% [3,4]. While carriage rates
re very variable among human populations, point-prevalence car-
iage rates in Europe and the United States have been estimated to
ange from 10 to 35% in young adults [5–8] and it is likely that, at
ne time or another during life,most individuals are colonizedwith
eningococci.
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As is the case with other bacterial inhabitants of the mucosa,
such as Haemophilus inﬂuenzae and Streptococcus pneumoniae, N.
meningitidis has a clear pathogenic potential. Shortly after col-
onization, and usually less than 10 days from ﬁrst exposure,
meningococci can pass through the epithelial cells and enter
the blood stream, where they occasionally survive and multiply
intravascularly. Progression to severe meningococcal disease can
occur very rapidly. The most important factors predisposing indi-
viduals to invasivemeningococcal disease are the lack of circulating
protective bactericidal antibodies and defects in the complement
system. From the blood stream the bacterium is then disseminated
to various organs and more than half of the patients developing a
systemic meningococcal infection will present with clinical symp-
toms of meningitis [9]. Meningococcal disease is a life-threatening
illness and, despite appropriate treatment, the case fatality rate is
still around 10% [10].
2. Meningococcal carriage
Studies of meningococci isolated from the nasopharynx, which
is the normal environment of the meningococcus, are essential to
improve knowledge of the epidemiology of meningococcal disease.
Open access under CC BY license.The results of carriage studies, however, are highly dependent on
the swabbing techniques and laboratory methods used. Swabbing
of the posteriorwall of the oropharynx, followed by immediate cul-
tivation on selective medium, is the recommended procedure to
detect asymptomatic meningococcal carriage in an individual [11].
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ome real-time PCR methods have been attempted more recently,
ut their sensitivity is not greater than the microbiological tech-
iques based on culture [12,13].
Age is one of the most important factors inﬂuencing meningo-
occal carriage rates. In Europe and North America, carriage rates
re very low in the ﬁrst years of life, and then sharply increase in
eenagers, reaching a maximum in those aged between 20 and 24
ears. Carriage rates in older ages are lower than 10% [5,6,8,14].
tudies of meningococcal carriage in Africa, on the other hand,
ave shown very variable age distributions from one study to
nother that usually do not correspond to those from Europe and
orth America [15]. Other factors that increase the risk of being
meningococcal carrier include: male gender; coincident respira-
ory tract infections of viral or bacterial origin; active as well as
assive smoking; and low socio-economic status. One of the most
mportant factors is the number and closeness of social contacts
16].
Most carrier studies are cross-sectional surveys of a target pop-
lation at a single point in time, i.e. are snapshot studies. In
uch cases, a positive sample will not identify when the indi-
idual acquired the meningococcus and a negative sample might
e due to low sampling sensitivity. Some investigators, however,
ave attempted to measure duration of meningococcal carriage by
ollowing subjectswith repeated throat samples over time in longi-
udinal studies. These studies have shown that the meningococcal
arrier state may be chronic, lasting for several months, intermit-
ent, or transient [17,18].
To understand the dynamics of transmission ofN.meningitidis in
population, molecular characterization of the organisms is essen-
ial. In most carriage studies, isolate characterization to determine
hether the carried strain is the sameover time, has either not been
erformed or the methods employed were relatively insensitive. In
he past few years a number of longitudinal studies have employed
owerfulmolecularmethods to gain information on the duration of
arriage and acquisition rates in populations. These investigations
ave shown that the commensal association of particular strain
ith the host is a long-term relationship with 90% of stable car-
iers keeping the same strain for a period of 5–6 months [19,20].
onger follow-up periods are required to establish the duration of
arriage fully. Duration of carriage depends on the properties of
he colonizing strain, and not all meningococcal strains having the
ame propensity to establish a long-term commensal relationship
ith a given host.
. Meningococcal disease
Despite high rates of meningococcal carriage in many or most
uman populations, disease is rare with annual incidence rates
hat vary from 1 to 1000 cases per 100,000 individuals in different
arts of the world. With the exception of patients with comple-
ent deﬁciency, who are predisposed to meningococcal infections,
mmunocompetent individuals are unlikely to develop the disease
ore than once.
Meningococcal disease in Europe and North America usually
ccurs as sporadic cases and the highest age-speciﬁc incidence
ates are seen in children less than 5 years of age, which is in
ontrast to the low prevalence of asymptomatic carriage in this
ge group. The disease may also present different epidemiolog-
cal features. In some areas hyperendemic disease occurs, with
ncidence rates of 5–10 cases per 100,000 and these increased inci-
ence waves can last for several decades. Cases can also occur
n clusters and localized outbreaks, but the most dramatic epi-
emiological manifestations are the periodic large countrywide
pidemics or pandemics that occur in some parts of the world.
urrently, epidemic and pandemic disease appears restricted tocine 27S (2009) B64–B70 B65
countries of sub-Saharan Africa, in the so-called “meningitis belt”,
which extends fromEthiopia in the East to Senegal in theWest [21].
The capsular polysaccharide is the outermost structure on the
meningococcal surface. Of the 12 serogroups identiﬁed on the basis
of antigenic variation of the capsule, 5 (A, B, C, W135, and Y) are
responsible for more than 90% of the invasive disease worldwide
andhave been associatedwith hyperendemic and epidemic disease
[22]. Recently, a sixth serogroup, serogroup X, has also revealed
an epidemic potential [23]. The capsule, which protects the bac-
terium during the invasion process, is a major virulence factor and
the primary target for mucosal and humoral immunity. The cur-
rently commercially available meningococcal vaccines target the
serogroup A, C, Y and W135 polysaccharides.
The large epidemics in Africa have been, with a few exceptions,
associated with serogroup A meningococci, which have essentially
disappeared from Europe and North America since World War II
[24,25]. Serogroup B meningococci, which are generally absent in
sub-SaharanAfrica, are the primary concern in industrialized coun-
tries, where they have been responsible for hyperendemic waves
of disease. Outbreaks of serogroup C meningococcal disease occur
worldwide, especially in adolescents and young adults [26] and
serogroup Y meningococci have emerged as an important cause
of disease in North America in the past 10 years or so [27], while
serogroup W135 and X meningococci have been responsible for
epidemics in sub-Saharan Africa since 2002 [28].
4. Genetic methods for isolate characterization
Multilocus sequence typing (MLST) was ﬁrst developed in the
late 1990s for the meningococcus [29]. It is a high reliable and
reproducible characterization method, which assesses variation at
multiple genetic loci using nucleotide sequencing. MLST has a very
high discriminatory power and the generated data can be read-
ily exchanged among laboratories, through a centralized, curated
Internet-accessible database (http://pubmlst.org/neisseria). Devel-
oped by a European consortium, the method was readily adopted
as the reference genotyping method for N. meningitidis by scien-
tists worldwide [30–33]. The success of MLST in application to
meningococci resulted in development of similar typing schemes
for numerous other bacterial pathogens (see www.mlst.net;
www.pubmlst.org).
The general acceptance of MLST over the past of 10 years has
enabled the assembly of a public repository of genotypic data rep-
resenting well over 10,000 meningococcal isolates from both cases
of disease and carriers in various parts of the world. This is an
extremely valuable source of information relevant to understand-
ing theepidemiologyandpopulationbiologyof themeningococcus.
Data from additional genetic methods can be superimposed on the
genetic framework provided by MLST to provide further insights
into the evolutionary potential of N. meningitides—such methods
include the sequencingof genes coding for various antigens [34–36]
and analyses of patterns of insertion of insertion sequence (IS) ele-
ments [37] and variable number tandem repeats (VNTRs) [38,39].
5. Genetic structure and evolution of meningococci
5.1. Meningococcal genetic variation
The meningococcus is the best-characterized member of the
genus Neisseria (94% of the sequence types (STs) listed on the
PubMLST Neisseria database are meningococcal). The species is
genetically and antigenically highly diverse: 6751 STs had been
assigned at the time of writing. Sequence typing has also iden-
tiﬁed hundreds of variants and sub-variants of putative vaccine
components, such as the PorA outer membrane protein (OMP)
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http://neisseria.org/nm/). Extensive genetic exchange among
eningococci [40–44] has major implications in combating
uman disease, both in confusing epidemiological investigations
nd in complicating vaccine design. Sub-capsular protein variation
s especially important, as the development of serogroup B polysac-
haride vaccines has been inhibited by poor immunogenicity and
ears of inducing autoimmune responses [45].
While meningococcal diversity is extensive, it is highly struc-
ured. Studies of variation at housekeeping loci, initially by
ultilocus enzymeelectrophoresis [46] andmore recently byMLST
29], had identiﬁed 37 groups of closely related meningococci at
he time of writing, accounting for 61% of the meningococcal iso-
ates represented in the PubMLST database. These groups, known
s clonal complexes, have become the predominant unit of analy-
is in meningococcal population biology and epidemiology [26]. A
inority of clonal complexes, the so-called hyperinvasive lineages,
re responsible for a disproportionate number of cases of disease
orldwide [26] and can be over-represented in collections of iso-
ates fromdiseasedpatients by asmuchas twoorders ofmagnitude,
elative to their prevalence in asymptomatic carriage (Table 1) [47].
ne of them, in particular, the ST-11 clonal complex, is remarkable
or its very low rates of carriage relative to high incidence of dis-
ase [47,48]. Notwithstanding the high levels of horizontal genetic
xchange, clonal complexes, especially hyperinvasive lineages, are
table over time with life spans of many decades and during global
pread [26]. This stability and the association of clonal complexes
ith particular antigenic repertoires provides some hope that the
evelopment of protein-based vaccines may be possible, if the
ature anddynamics of this structuring canbeproperly understood
35,36,49].
The propensity to cause disease is polygenic, depending on com-
inations of genes or allelic variants of genes also present in less
nvasive meningococci [50]. Various attempts have been made to
dentify the genetic elements that are associated with invasion
51,52], but to date the capsule region, encoding the ability to
ynthesise a polysaccharide capsule [53], remains the principal ‘vir-
lence determinant’. As a virulence determinant, however, even the
ole of capsule is ambiguous as only 5 or 6 of the 12 capsule vari-
nts are ever associated with a signiﬁcant number of disease cases.
hile capsule expression isusually considerednecessary (although
are cases caused by non-encapsulated meningococci have been
able 1
haracteristics of the most important clonal complexes of Neisseria meningitidis (data com
T-complex MLEE designation No. isolates No. STs Dominant serogroup
T-1 complex Subgroup I/II 204 49 A(97)
T-5 complex Subgroup III 627 33 A(99)
T-8 complex Cluster A4 283 107 B(51),C(35)
T-11 complex ET-37 complex 1142 239 C(57),W135(24),B(1
T-18 complex Cluster J1 208 175 B(85)
T-22 complex 363 243 W135(52),NG(25)
T-23 complex Cluster A3 385 154 Y(62),NG(18)
T-32 complex ET-5 complex 1028 350 B(85)
T-35 complex 329 214 B(59),NG(25)
T-41/44 complex Lineage 3 1796 1274 B(70)
T-53 complex 272 93 NG(76)
T-60 complex 225 148 B(30),29E(22),NG(19
T-103 complex 127 84 B(26),NG(22),C(16)
T-162 complex 140 63 B(74),NG(13)
T-167 complex 201 144 Y(47),NG(36)
T-198 complex 166 76 NG(76)
T-213 complex 187 165 B(74),NG(16)
T-254 complex 148 107 NG(35),B(24),29E(12
T-269 complex 415 312 B(73)
T-334 complex 106 64 C(58),B(33)
a This ratio is calculated on from data deposited the PubMLST database, which contains
lthough it represents a comprehensive overview of the diversity observed to date, this d
f disease to carrier ratios for particular populations are available in Refs. [47,77].cine 27S (2009) B64–B70
reported in immunocompetent patients [54–56]), it is not sufﬁcient
for a meningococcus to cause disease. In contrast to the disease
causing strains, approximately 50% of the isolates from healthy
carriers do not express a capsule [57]. Further, 16–20% of car-
ried meningococci do not possess the capsular gene region which
encodes the genes required to synthesise the capsule [58–60].
In addition to nucleotide sequence variation at shared loci
meningococci exhibit extensive variation in gene content. This has
been explored by the comparison of whole or partially sequenced
genomes [61–65]. Meningococcal genome structure is also diverse
in various other ways, including the presence and absence of ISs
and large repertoires of repeat elements of various sizes, tracts of
repeated nucleotides, and short nucleotide repeats [63,66]. Many
of these are involved in mechanisms of gene regulation and at least
65 genes show potential for highly variable gene expression [67].
These ‘contingency genes’ [68]must have evolved as ameans of sur-
viving during carriage, perhaps for immune evasion or exploitation
of microniches on the mucosal surface. Which genes are expressed
and when has a major inﬂuence on the development of disease.
For example, many meningococci express capsules during trans-
mission, but downregulate this expression during carriage [69].
Invasion of the mucosal epithelium requires the meningococcus to
be acapsulate, but once in the bloodstream meningococci must be
capsulate to grow to cause bacteraemia. Tropism to the meninges
also requires the expression of different genes. The role of differen-
tial gene expression during invasion and spread remains to be fully
deﬁned.
The existence of deﬁned genetic types with different pheno-
types provides the prospect of identifying the genetic traits that
are responsible for those phenotypes by genome wide association
studies [70] performed with well-deﬁned isolate collections [71].
To date studies of differences in gene content have failed to detect
consistent gene content differences among the Neisseria species,
with themajority of genes shared among themeningococcus, gono-
coccus and N. lactamica [72,73], notwithstanding their consistently
different relationships with humans [71]. Genomic studies have, by
and large, also failed to identify major differences among meningo-
cocci that havenot beenpreviously identiﬁedbymore conventional
molecular microbiology [74,75]. Several genome wide association
studies have been undertaken within the meningococcus but, as
yet, the only new element to be associated with meningococcal
piled from the PubMLST database 6/02/09).
s (%) Dominant
PorA
Dominant
FetA
Disease/carriage
ratioa
Main origin
5-2,10 F3-5 5.5 Russia, China
20,9 F3-1 19.5 Africa
5-1,2-2 F3-6 24.5 Europe
2) 5,2 F3-6 6.6 Worldwide
22,14 F3-6 5.5 Czech Republic, Poland
18-1,3 F4-1 0.6 UK
5-1,2-2 F4-1 0.8 Worldwide
19,15 F5-1 3.5 Worldwide
22-1,14 F4-1 0.5 Worldwide
7-2,4 F1-5 1.2 Worldwide
7-2,30 F1-7 <0.1 UK
) 5,2 F1-7 0.7 Europe
18-1,3 F3-9 1.2 Worldwide (-Africa)
22,14 F5-9 0.8 Worldwide
5-1,10-4 F3-4 0.5 Worldwide
18,25-15 F5-5 <0.1 Worldwide
22,14 F5-5 0.6 UK
) 5-1,16 F1-7,F3-6 0.5 Worldwide
22,9 F5-1 2.8 Worldwide
5-1,2-2 F1-5 5.7 UK
only those isolates submitted to it by members of theNeisseria research community.
atabase is not a coherent population sample. More precise calculations of the ratio
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isease is a putative phage, identiﬁed by whole genome compar-
sons of disease and carriage isolates [76]. Intriguingly, although
his element is associated with particular clonal complexes, it has
measurable effect on the likelihood of a meningococcus caus-
ng disease, independent of this association. Further this effect is
redominantly seen in meningococci isolated from teenagers—the
lement is underrepresented in isolates from younger children and
ver-represented in adolescents [77]. With the advent of novel
igh through-put parallel sequencing, this ‘population genomics’
pproach is likely to provide further insights into meningococcal
iology in the immediate future [71].
.2. Meningococcal evolution
The meningococcus, in common with other members of the
enusNeisseria, is naturally competent for transformationbyexoge-
ous DNA and studies of horizontal genetic exchange among these
acteria [78–82] played an important role in the development of
odels of bacterial speciation and population structure at the sub-
pecies level. These studies are also important in understanding
eningococcal epidemiology and virulence. High observed recom-
ination rates inmeningococcal populations, togetherwith the fact
hat as the N. meningitidis is primarily a commensal organism that
ains no advantage from invasion of the host, poses two paradoxes:
i) how can clonal complex structure emerge and persist without
eing broken down by frequent recombination? and (ii) how can
ome of these clonal complexes be associated with a propensity to
ause disease, as meningococci that do not harm their hosts should
e favoured during asymptomatic transmission? These paradoxes
ave to be addressed by models of meningococcal evolution and,
iven that invasion of the host is an evolutionary dead-end, such
odels need to be tested with data obtained from carried popula-
ions of meningococci.
Although recombination has attracted interest as a mech-
nism for generating diversity [83], much – indeed most –
enetic exchange is almost certainly among very closely related
eningococci (i.e., sister cells), and will therefore be conservative,
omogenising, and normally unobservable, as it will involve the
eplacement of a segment of the genomewith an identical segment.
upport for this viewhas come from the observation of a strong link
etween recombinationandNeisseriaDNAuptake sequences (DUS).
hese short sequences, which promote the uptake of Neisseria DNA
y other Neisseria, are concentrated in regions of the genome that
ncode DNA maintenance and other ‘core’ Neisseria genes [84] sug-
esting that theymay be important in genome stability [85]; if their
ole was principally in generating diversity it would be expected
hat they would be sparse in core conserved genes and common in
ighly variable genes.
The distribution of DUS is therefore consistent with recom-
ination being primarily a mechanism for genome repair that
an occasionally result in generation of diversity, which, even
ore occasionally, is adaptive. It may be that this repair func-
ion is especially important in the Neisseria, which lack several
NA repair genes [66]; this is also consistent with the distribu-
ion of restriction modiﬁcation systems among meningococci, with
articular systems associated with given clonal complexes [86].
he restriction modiﬁcation systems may therefore act to promote
enetic exchange among very close relatives while reducing (but
ot absolutely preventing) genetic exchange among meningococci
elonging to different clonal complexes and related species.
Clonal complex structure, which is such a feature of meningo-
occal populations, can be explained by models of clonal descent
ith periodic selection [87], but such models are not consistent
ith the lack of a clonal phylogeny of meningococci [42], and high
bserved rates of recombination [44]. The ‘epidemic’ [88] and, later,
neutral microepidemic’ models [89] of population structure werecine 27S (2009) B64–B70 B67
developed to accommodate clonal complex structure in recombin-
ing populations. Thesemodels envisage structure inmeningococcal
populations reﬂecting short-term dominance of particular clones
and can explain the patterns of variation seen in cross-sectional
surveys quite well [89]. These models cannot, however, explain the
persistence of clonal complex structures or the association of some
lineages with the hyperinvasive phenotype [90].
Alternative dynamicmodels explore the organisation of popula-
tions into strains in the context of selective forces [91]. Structuring
of antigen variants encoded at multiple loci can be explained in
meningococci, and other recombining pathogens such as Plasmod-
ium falciparum, by immune selection acting on them. Depending
on the intensity of positive selection, i.e., the strength of the
immune interactions with the antigens, a range of different pop-
ulation structures can be generated. Importantly, the antigenic
repertoires of strains generated by this mechanism will be charac-
teristically non-overlapping, in that the different strains circulating
in the population will not share variants at each of the loci under
selection. Such non-overlapping repertoires have been observed in
the meningococcal surface genes, especially the porins and Opa
proteins [90,92,93]. The consequent limitations of the repertoires
of such antigens available to circulating meningococci therefore
have major implications for rational vaccine design [35,36]. These
immunological models can also explain clonal complex structure if
the combinations of housekeeping genes were hitch-hiking with
genes encoding the antigenic variants repertoire; however, the
antigenic structuring although mirroring clonal complex, is not
always congruent with it, with some members of the same clonal
complex exhibiting different antigenic repertoires and occasional
examples of the same antigen occurring in different clonal com-
plexes. Combined with high rates of recombination, this makes
hitch-hiking an unlikely explanation for clonal complex struc-
ture.
A major limitation of all of the models discussed so far is that
they provide no explanation for the association of certain clonal
complexes with an increased propensity to cause disease. If, how-
ever, the clonal complexes are regarded as units of selection, with
particular STs being associated with ﬁtness for transmission, both
clonal complex structure and the hyperinvasive phenotype can be
explainedwithin the context of competition for hosts among differ-
ent meningococcal genotypes [90]. This insight has the important
implication that the observed genetic structuring must have a phe-
notypic consequence. If this is the case, STs are subject to selection
and not neutral markers as previously thought; the model further
demonstrates that ﬁtness differences among distinct types are very
small [90]. These insights are complementary to a stochastic model
of meningococcal disease outbreaks, which showed that for large
disease outbreaks, very small differences in pathogenic potential
are necessary [94]. Diversity, and the forces which structure it,
therefore appear to be central to the biology and pathogenicity of
meningococci.
6. Implications for vaccine design
Meningococcal disease remains incompletely controlled by
immunisation, largely as a consequence of the diversity of N.
meningitidis populations. In terms of vaccine candidates, the exis-
tence of ﬁve, or at most six different polysaccharide capsules is
not a challenge, given the successful implementation of conju-
gate polysaccharide vaccines available against pneumococci that
contain multiple components [95]. However, the fact that the
meningococcal serogroup B capsular antigen is chemically similar
to the host antigen NCAM [96] has raised safety concerns that have
precluded the development of comprehensive capsular vaccines
against the meningococcus [45].
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The immunology of conjugate polysaccharide vaccines that tar-
et meningococcal capsules was thought to be well understood
t the time of their introduction into national immunisation pro-
rams [97,98]. The conjugation of the polysaccharide to a protein
licits a T-cell-dependent immune response and immunological
emory, both of which are absent when pure polysaccharide is
sed as an immunogen. Studies of carriage during vaccine intro-
uction in the United Kingdom, together with continued disease
urveillance in countries where the vaccines have been introduced,
ave demonstrated an additional powerful herd immunity effect.
s well as providing strong personal protection, meningococcal
onjugate vaccines protect the population, including unvacci-
ated individuals, by interrupting the transmission of capsulate
eningococci [99,100]. Intriguingly in the UK this effect was
trongly directed at serogroup C meningococci belonging to the
T-11 complex and made a major contribution to the success
f this vaccine introduction [48]. The magnitude of this effect
ould be attributed to the inclusion of teenagers, among whom
ost meningococcal transmission occurs, in the immunisation
ampaign [16]. Carriage studies therefore provide an additional
ay of monitoring the effectiveness of immunisation pro-
rammes, as well as indicating the most efﬁcient implementation
trategies.
Although providing an apparent alternative to conjugate
olysaccharides, especially in thecaseof serogroupBmeningococci,
he sub-capsular antigens provide challenges of their own [45].
here sub-capsular vaccines, particularly the outer membrane
esicle vaccines, have been successful this has been a consequence
f their effectiveness against particular hyperinvasive lineages, and
heir design has been based on epidemiological knowledge of the
revalent disease causing lineages [101–103]. These approaches
ill, however, have a limited impact on disease caused by a vari-
ty of hyperinvasive meningococci, such as its typical of endemic
isease in Europe and North America [104,105], and there is lit-
le evidence of effective herd immunity induced by such vaccines.
herefore, if sub-capsular vaccines are to be effective against a
road range of meningococci, they will either have to be based on
ajor surface components that are antigenically invariant and reli-
bly expressed in all or most disease-associated meningococci (if
uch components indeed exist, which remains an open question)
r they will have to contain cocktails of vaccine antigens care-
ully formulated on the basis of the molecular epidemiology of the
eningococcus [106]. In either case, knowledge of the molecular
pidemiology and evolution of disease and carried meningococci
ill be central to the design implementation and assessment of
uch vaccines.
In conclusion, studies of the carrier state of the meningococ-
us remain of central importance in combating this important
athogen. Understanding the spread of invasive meningococci
epends on appreciating the natural history of the organism and
eﬁning thedynamics of asymptomatic transmission. Resolving the
pparent paradox of meningococcal virulence depends on reﬁning
odels of meningococcal evolution, a process that occurs exclu-
ively during carriage and transmission. Finally, the design and
ptimal use of meningococcal vaccines depends on acknowledging
heir effect on carriage. While much had been learned concerning
ach of these subjects over the last decade, much remains to be
lucidated in this intriguing and important area of meningococcal
iology.
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